Theraclone Sciences, a Seattle biotechnology company that’s developing a method to rapidly identify disease-fighting antivbodies, has attracted $10.6 million. Investors in the deal include ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo
“The anticipated near-term initiation of Theraclone’s first clinical trial and our discovery collaboration with Pfizer earlier this year are important milestones that demonstrate Theraclone’s continued progress with our R&D pipeline and technology platform. The continued support from our investors represents both a vote of confidence and an ability to sustain our rapid pace of activity and progress,” said Steven Gillis, a venture capitalist at Arch Venture Partners who is serving as acting CEO.
Earlier this year, Theraclone scored a cancer research deal with drug giant Pfizer valued at as much as $632 million.
Founded as Spaltudaq in 2005 at the Seattle-based Accelerator, Theraclone has raised a total of $41 million in its second round of financing.
